Stock Events

Beam Therapeutics 

M$450
0
+M$10+2.27% Tuesday 19:46

Statistics

Day High
450
Day Low
448.8
52W High
806
52W Low
440
Volume
4,900
Avg. Volume
1
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

27FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-1.56
-0.46
0.63
1.73
Expected EPS
-1.01
Actual EPS
1.73

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BEAM.MX. It's not an investment recommendation.

About

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Show more...
CEO
John M. Evans
Employees
436
Country
US
ISIN
US07373V1052

Listings